Outcomes of study participants
| Number of events/at risk | Rate (95% CI) per 100 person-years | HR (95% CI) (unadjusted) | P values | HR (95% CI) (adjusted*) | P values | HR (95% CI) (adjusted†) | P values | |
| Death‡ | ||||||||
| NCTHF | 170/894 | 4.4 (3.8 to 5.1) | Ref | Ref | Ref | |||
| CTHF | 17/75 | 5.2 (3.3 to 8.4) | 1.21 (0.73 to 1.99) | 0.46 | 2.24 (1.32 to 3.79) | 0.003 | 2.64 (1.53 to 4.55) | 0.001 |
| Composite endpointठ| ||||||||
| NCTHF | 235/894 | 6.4 (5.7 to 7.3) | Ref | Ref | Ref | |||
| CTHF | 21/75 | 6.7 (4.4 to 10.3) | 1.05 (0.67 to 1.64) | 0.84 | 1.57 (0.99 to 2.51) | 0.057 | 1.79 (1.10 to 2.91) | 0.019 |
The composite endpoint was defined as the composite outcome of left ventricular assistant device (LVAD) implantation, heart transplantation or all-cause mortality.
*Adjusted for age and sex.
†Adjusted for age, sex, ejection fraction, chronic kidney disease, resting heart rate, resting systolic blood pressure, pacemaker use, peak VO2 and VE/VCO2 relationship.
‡Median follow-up: CTHF group=4.7 (3.0 to 5.9) years; NCTHF group=4.4 (3.0 to 5.8) years.
§The composite endpoint included 4 LVAD, 3 transplants and 14 deaths in the CTHF groups; and 58 LVAD, 25 transplants and 152 deaths in the NCTHF group.
CTHF, cancer therapy-induced heart failure; NCTHF, non-cancer therapy-induced heart failure.